Brainstorm cell therapeutics announces second quarter 2024 financial results and provides corporate update

- company reached alignment with the u.s. fda on the chemistry, manufacturing, and controls (cmc) aspects of its planned phase 3b clinical trial for nurown® in als - spa in place for phase 3b nurown® trial in als - enhanced leadership team with appointment of  hartoun hartounian ph.d. as evp and chief operating officer, and promotion of dr. bob dagher to evp and chief medical officer - conference call and webcast at 8.30am et today new york , aug. 14, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended june 30, 2023 and provided a corporate update.
BCLI Ratings Summary
BCLI Quant Ranking